Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma
This study has been completed.
Study NCT00022945 Information provided by Corixa Corporation
First Received on August 16, 2001. Last Updated on June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Mantle Cell Lymphoma
Additional conditions recognized in this trial
Lymphoma
Lymphoma, Mantle-Cell
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
Iodine-131 Anti-B1 Antibody
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Cadexomer iodine
Cyclophosphamide
Doxorubicin
Immunoglobulins
Iodine
Prednisone
Vincristine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Anti-Infective Agents, Local
Anti-Inflammatory Agents
Antibiotics, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Phytogenic
Antirheumatic Agents
Glucocorticoids
Growth Substances
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Immunologic Factors
Immunosuppressive Agents
Micronutrients
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Trace Elements
Tubulin Modulators
Sponsors listed in this trial
Corixa Corporation
Back to top of Main Content
